Search

Displaying results 6151 - 6160 of 9887 in total
  1. Drug

    Forodesine

    go.drugbank.com/drugs/DB06185
    Investigational

    Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic

    Synonyms: (1S)-1,4-dideoxy-4-imino-(9-deazahypoxanthin-9-yl)-D-ribitol, 1,4-Dideoxy-4-aza-1-(S)-(9-deazahypoxanthin-9-yl)-D-ribitol
  2. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    Atrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

    Categories: Endothelin A Receptor Antagonists
  3. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    a 68% reduction in the risk of death were observed. … This approval is based on positive results obtained from a multi-site, single-arm, externally controlled study of children with high-risk neuroblastoma, where a 52% reduction in the risk of relapse and

  4. Drug

    Elinogrel

    go.drugbank.com/drugs/DB06350
    Investigational

    A P2Y12 inhibitor and platelet aggregation inhibitor.

  5. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals.

  6. Drug

    Armodafinil

    go.drugbank.com/drugs/DB06413
    ApprovedInvestigational

    (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.

  7. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    Patients are advised to immediately contact their healthcare provider if a rash develops. … Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI).

  8. Drug

    Aplaviroc

    go.drugbank.com/drugs/DB06497
    Investigational

    A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

  9. Drug

    Resiquimod

    go.drugbank.com/drugs/DB06530
    Investigational

    It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator. … A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells.

  10. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index